VIDEO: Disease control major unmet need for diabetic macular edema

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Diabetic macular edema is also a very challenging disease to treat because patients have to come back frequently for evaluations with their retina specialists and treatment. We realize that patients with diabetes have multiple medical conditions, and it’s challenging for them to take off work or have their caregivers come with them to these office visits. The unmet need still is to control their disease while having longer intervals between treatments. I think many of the new drug developments that have been recently FDA approved, 8 mg of aflibercept or faricimab, are trying to address this unmet need, while controlling their ocular disease and preventing reactivation, while preserving their visual outcomes. We hope that additional therapies under investigation will continue to develop better control of vascular permeability while maintaining excellent vision outcomes.